AI can now author viral genomes, not just analyze biology. This isn't science fiction; it's a peer-reviewed reality published in Science. Experts are raising urgent biosafety and biosecurity questions.
Signal register
Signals from X
Public posts, experimentally classified on three axes: public impact, the systems that fail, and the industries in the blast radius. Estimates only — not a formal assessment.
Methodology — experimental estimates
Scores are automated, experimental estimates from public X posts and a hand-written seed corpus. They are not formal risk assessments, not certified, and not suitable for compliance or operational decisions.
Consequence, likelihood, and urgency are 1–5 judgements applied by this project, not by a standards body. Residual scores assume only the mitigations marked in place. A signed-in reviewer can override residual and mark an item reviewed — that override is still unofficial. Aspect tags (capability, domain knowledge, affordance, impact domain) are a lightweight PRA aid, not a formal hazard analysis.
FDA floats doctor-style “competency” testing for GenAI medical devices in a new discussion paper on risk, premarket eval & postmarket monitoring. Comment period open until October 19 as US aims to set the global model/standard. https://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices
More than 300 million people turn to ChatGPT with health-related questions each week—and we’re continuing to improve how our models respond. We work with hundreds of physicians around the world to measure and improve accuracy, safety, communication, context awareness, completeness, and appropriate escalation.